



VISIBLE COHORT B: GUSELKUMAB DEMONSTRATED SCALP CLEARANCE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE SCALP PSORIASIS ACROSS ALL SKIN TONES

¹Wake Forest School of Medicine, Winston-Salem, NC, USA; ²Synergy Dermatology, San Francisco, CA, USA; ⁴Johnson & Johnson, Horsham and Spring House, PA, USA; ⁵Dermatology Treatment and Research Center, Dallas, TX, USA; ⁶University of Toronto, Toronto, ON, Canada; ⁷Northwell Health Physician Partners, New York, NY, USA; ⁸University of Pennsylvania, Philadelphia, PA, USA

E is an ongoing Phase 3b, multicenter, randomized, doubleplacebo (PBO)-controlled study of guselkumab (GUS) for the ⁱ participants with moderate-to-severe plaque psoriasis



Week 16, and response rates were sustained or increased at Week 48



Pharma, Eli Lilly, and Pfizer. **Previously presented at** American Academy of Dermatology; March 7-11, 2025; Orlando, Florida.

Presented at 2025 Congress of Clinical Dermatology; May 29-June 1, 2025; Amelia Island, Florida.

A. McMichael,¹ T. Bhutani,² S. Smith,³ T. Alkousakis,⁴ O. Choi,⁴ D. Chan,⁴ T. Ma,⁴ R. Radusky,⁵ J. Yeung,⁶ G. Han,⁷ S.C. Taylor⁸



Scan the QR code. provide scientific information nformation should not be alter or reproduced in any way.

Key Safety Information	PB0-→GUS° (Weeks 16-48)	GUS (Weeks 0-48)
Safety analysis set, N	24	81
Average duration of follow-up (weeks)	31.1	47.7
Participants with ≥1 AE	9 (37.5)	51 (63.0)
Participants with \geq 1 AE leading to discontinuation of study agent	0	0
Participants with ≥1 SAE	0	2 (2.5) ^f
Participants with \geq 1 injection-site reaction	0	1 (1.2)
Infections	4 (16.7)	27 (33.3)
Serious infections	0	0